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Abstract
Background: The aim of this study was to explore the feasibility of using a non-absorbable biocompatible
polyester patch to augment open repair of massive rotator cuff tears (Patch group) and compare outcomes with
other treatment options (Non-patch group).
Methods: Participants referred to orthopaedic clinics for rotator cuff surgery were recruited. Choice of intervention (Patch or
Non-patch) was based on patient preference and intra-operative findings. Oxford Shoulder Score (OSS), Shoulder Pain and
Disability Index (SPADI), and Constant score were completed at baseline and 6months. Shoulder MRI was performed at
baseline and 6months to assess fat fraction and Goutallier classification pre- and post- treatment. Feasibility outcomes
(including retention, consent and missing data) were assessed.
Results: Sixty-eight participants (29 in the Patch group, 39 in Non-patch group) were included (mean age 65.3 years).
Conversion to consent (92.6%), missing data (0% at baseline), and attrition rate (16%) were deemed successful
feasibility endpoints. There was significant improvement in the Patch group compared to Non-patch at 6 months in
OSS (difference in medians 9.76 (95% CI 2.25, 17.29) and SPADI: 22.97 (95% CI 3.02, 42.92), with no substantive
differences in Constant score. The patch group had a higher proportion of participants improving greater than MCID
for OSS (78% vs 62%) and SPADI (63% vs 50%) respectively. Analysis of the 48 paired MRIs demonstrated a slight
increase in the fat fraction for supraspinatus (53 to 55%), and infraspinatus (26 to 29%) at 6 months. These differences
were similar and in the same direction when the participants were analysed by treatment group. The Goutallier score
remained the same or worsened one grade in both groups equally.
Conclusions: This study indicates that a definitive clinical trial investigating the use of a non-absorbable patch to
augment repair of massive rotator cuff tears is feasible. In such patients, the patch has the potential to improve
shoulder symptoms at 6 months.
Trial registration: ISRCTN, ISRCTN79844053, Registered 15th October 2014 (retrospectively registered).
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Background
In the United Kingdom, 2.4% of all primary care consul-
tations involve shoulder problems, and of these around
70% have rotator cuff pathology affecting their daily liv-
ing [1, 2]. The prevalence of massive cuff tears ranges
from 6.4–12% [3–5] with the management of symptom-
atic large and massive rotator cuff tears (RoCTs) pre-
senting significant problems to the shoulder surgeon [6].
Repair of symptomatic RoCTs results in better clinical
results compared to conservatively managed tears [7, 8].
Rates of re-rupture following repair vary significantly
(7–46%) [9, 10] but for massive tears can be as high as
94% [8]. Commonly reported risk factors for failure are
poor tendon quality, fatty atrophy, number of tendons
involved, pre-operative tear size, tension on repair and
patient age [11–14].
The management of large and massive RoCTs in shoul-
ders with minimal arthritis remains a dilemma for shoul-
der surgeons [15, 16] . There are many options available,
including specialised rehabilitation, simple arthroscopic
surgery including debridement [17–20], long head of bi-
ceps tenotomy, bursectomy [21, 22], various tendon trans-
fers [23, 24] through to formal repair of the tendon. This
may be in the form of partial repair or complete repair
where achievable. Current published outcomes for all
these measures have been relatively successful, but re-tear
rates are often high, and clinical outcomes can deteriorate
after 2 years [25, 26]. This has therefore led to the devel-
opment of further techniques, including use of patch to
augment repair, subacromial spacer insertion and superior
capsular reconstruction [27].
Surgeons have also investigated the use of patch grafts
to bridge or augment larger tears in poor quality tendons
with promising results [28–30]. However, these reports
are predominantly case series with no attempt to compare
the results with other, sometimes simpler, surgical options
which may provide satisfactory outcomes [21, 31, 32]. The
James Lind Alliance have also highlighted the need to
examine different management options for repair of rota-
tor cuff tears as a priority area of research [33].
We conducted a study to determine the feasibility of
conducting a randomised controlled trial using patch-
assisted surgery; and to compare the clinical outcomes
and MRI findings of patients with massive RoCTs who
were managed with patch-assisted surgery against pa-
tients managed with traditional options (non-surgical




The Shoulder Patch for Rotator Cuff (SPARC) study was
a pragmatic, two-arm feasibility study. The study proto-
col was approved by Leeds West Research Ethics
Committee (13/YH/0030) and registered on ISRCTN
(ISRCTN79844053). Written informed consent was ob-
tained for all participants prior to screening. Participants
were recruited from 1st September 2013 to 20th Octo-
ber 2014. For the purposes of this feasibility study par-
ticipants were followed up for 6 months (follow-up
completed 20th October 2015).
Setting and participants
Participants were recruited through the Leeds Teaching
Hospitals NHS Trust orthopaedic clinics upon referral for
rotator cuff surgery. Participants were eligible if they had
ultrasound or magnetic resonance imaging (MRI) findings
confirming massive rotator cuff full thickness tears
(RoCT) (> 5 cm in size), with unacceptable pain and dis-
ability following conservative treatment or previous sur-
gery that had failed and would be considered for patch
surgery under routine clinical practice. Exclusion criteria
were age < 18 years old; history of infection in the shoul-
der; neurological condition affecting the shoulder girdle;
presence of rotator cuff arthropathy (secondary osteoarth-
ritis of the glenohumeral joint as a result of a rotator cuff
tear); current treatment for malignancy; pregnancy or lac-
tation; currently participating in other research studies; or
inability to give informed consent. Participants with con-
traindications to MRI were included but did not take part
in the MRI component of the study.
Treatment allocation and interventions
The particular intervention was determined in consultation
between the surgeon and the participant (Fig. 1 and Add-
itional file 1: Table 1). Management decisions were made at
two stages. First, the surgeon and participant jointly made a
decision between either conservative management (the an-
terior deltoid rehabilitation programme) or surgery. Second,
an intraoperative decision on surgical management was
made by the surgeon. If the torn tendon was mobile and
could be pulled back to the tuberosity, arthroscopic repair
was performed; if the torn tendon could be mobilised follow-
ing release to within 1 cm of the tuberosity to allow attach-
ment of a patch, repair was performed using a patch; and if
the torn tendon could not be mobilised following release, a
debridement was performed. In summary, participants in the
‘Patch’ group had elected surgical management and had
massive cuff tears which could not be fully reduced at sur-
gery but were suitable for repair by patch augmentation. The
‘Non-patch’ group had massive tears and elected for either
non-surgical rehabilitation, or surgical intervention involving
a procedure other than a patch.
Patch properties
The Leeds Kuff Patch (Xiros, Leeds UK) is produced
from polyethylene terephthalate (PET, polyester), a non-
absorbable biocompatible material that has been in use
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for the reconstruction of ligaments and tendons for over
25 years. Early generations of artificial tissue contained poly-
tetrafluorethylene and polypropylene, which resulted in in-
flammatory reactions within the surrounding tissues [34] .
However, more modern techniques and materials promote
new tissue ingrowth and minimize the occurrence of a for-
eign body reaction [35].
The design of the patch comprises a base component
with an integral reinforcement component. This base
component has an “open structure” that acts as a scaf-
fold allowing tissue ingrowth. The polyester is rendered
hydrophilic during the manufacturing process while the
reinforcement provides enhanced strength for the patch.
Outcome measures and follow-up
Participants were followed up for 6months with data col-
lected using standardised case report forms at baseline (pre-
treatment), 6 weeks and 6months post-treatment. At all
visits, clinical evaluations were performed. Baseline clinical
data collection included age, gender, body mass index, dur-
ation of symptoms, range of movement, previous treatments
for shoulder (including surgery), details of all therapies (in-
cluding use of intraarticular therapies) in the previous 12
months. Participants completed a series of patient reported
questionnaires at each visit to assess pain, function and pa-
tient satisfaction (Oxford Shoulder Score (OSS) [36], Shoul-
der Pain and Disability Index (SPADI) [37], and the
Constant Score [38] and quality of life was assessed using the
EuroQol five dimensions questionnaire (EQ-5D-5 L) [39].
An increase in the value of the OSS and Constant score at
follow-up represents improvement, while for SPADI, a de-
creased score represents improvement in pain and function.
Participants with no MRI contraindications had an MRI scan
at baseline and 6months.
MRI scans
MRI scans of the shoulder were performed using a pre-
agreed protocol using a MAGNETOM Verio 3.0 T MRI sys-
tem (Siemens Healthcare, Erlangen, Germany). Fat and water
images were generated from the Dixon images using the
scanner vendor’s software. B0 variations due to changes in
magnetic susceptibility at tissue interfaces were corrected for
using a phase correction method [40]. Imaging analysis was
performed using the OSIRIX system (Geneva, Switzerland).
Images were contoured on the fat only images from the spi-
noglenoid notch medially to the first slice showing continu-
ous bone marrow in the scapula laterally. This established a
reproducible volume in patients, which did not suffer from
Fig. 1 Treatment allocation flowchart. Intervention was determined in consultation between the surgeon and the participant. Management
decisions were made at two stages. First, the surgeon and participant jointly made a decision between either conservative management (the
anterior deltoid rehabilitation programme) or surgery. Second, an intraoperative decision on surgical management was made by the surgeon: if
the torn tendon was mobile and could be pulled back to the tuberosity, arthroscopic repair was performed; if the torn tendon could be
mobilised following release enough to allow attachment of a patch, repair was performed using a patch; and if the torn tendon could not be
mobilized following release, a debridement was performed
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signal drop off as previously described [41]. Regions of inter-
est (ROIs) were drawn for the purpose of measuring fat frac-
tion values. The 3 ROIs drawn outlined the supraspinatus
fossa, bounded superiorly by the trapezius muscle (SSP), the
suprapinatus remnant (SSP_RM) (defined as the muscle
remnant within the SSP) and the infraspinatus muscle
(Fig. 2). Fat fraction values were calculated for each ROI as
the mean voxel value in the fat image ROI divided by the
sum of the mean voxels values in the fat and the water im-
ages ROIs (fat/(fat+water)). Contouring was undertaken
using the methods adopted by Zanetti et al. [41] by a single
reader blinded to treatment allocation.
Muscles were also graded with the Goutallier Classifi-
cation [42] using the 0–4 grading system.
Sample size
As no hypothesis testing was anticipated no formal
power calculations were performed. Published evidence
for pilot study sample size suggests that 30 patients per
group represent a good balance between accuracy of ef-
fect size estimation and feasibility [43–46]. Therefore we
aimed to recruit 60 patients in total. Early in the study
the protocol was amended to enable over-recruitment in
order to allow for the recruitment of participants who
met study criteria but were ineligible for MRI whilst still
ensuring a total of approximately 60 participants took
part in the MRI component of the study.
Statistical analysis
Statistical analysis was conducted using STATA soft-
ware, version 13 (College Station, TX, USA 2013). To
understand feasibility, methodological issues relevant to
this study were reported according to the framework de-
vised for feasibility studies by Shanyinde et al. [47, 48].
Recruitment and eligibility was assessed using rate of eli-
gibility (%), the conversion of eligible to consent (%) and
Table 1 Demographic and baseline characteristics
Characteristic Patch (n = 29) Non-patch (n = 39) P-value
Age, years, mean ± SD 65.17 ± 8.98 65.38 ± 9.44 0.93
Sex, male 13 (46) 13 (33) 0.28
BMI, kg/m2, median (IQR) 29.71 (26.17–31.24) 26.75 (24.74–31.49) 0.69
Smoking status
Current smoker 3/28 (11) 2/39 (5)
Previous smoker 13/28 (46) 20/39 (51)
Never smoked 12/28 (43) 17/39 (44)
Cigarettes per day, median (IQR) 10 (5–20) 10 (10–20) 0.80
Employment history
Employed 8/28 (29) 7/39 (18)
Self-employed 1/28 (4) 4/39 (10)
Unemployed n/a 5/39 (13)
Retired 19/28 (67) 23/39 (59) 0.13
Job activity (current/previous)
Heavy manual 7/14 (50) 13/39 (48)
Desk based 3/14 (21) 8/39 (30)
Combined 4/14 (29) 6/39 (22) 0.71
Medical history
Duration of symptoms, median (IQR) 11.5 (6–20) 12 (6–24) 0.64
Previous physiotherapy 19/28 (68) 29 (74) 0.56
Previous IA injection 9/27 (33) 12/36 (33) 0.99
Previous operation 4/28 (14) 7 (18) 0.48
Oxford score,median (IQR) 28.00 (21–34) 25.00 (20–30) 0.24
SPADI,median (IQR) 46.92 (30.77–71.54) 54.61 (42.31–66.92) 0.56
EQ-5D- Index, median (IQR) 0.70 (0.53–0.82) 0.72 (0.55–0.80) 0.87
Eq-5D- VAS, mean (SD) 70.6 (17.7) 74.0 (18.0) 0.43
Constant score,median (IQR) 44.00 (27–54.5) 42.00 (33.5–51.92) 0.75
Values are N (%) unless stated
Results from t-test, Mann-Whitney, chi-square test and Fisher’s exact test where appropriate
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an assessment of whether required numbers sought were
recruited. Adherence to the protocol was assessed quali-
tatively by broadly reviewing the study objectives against
our findings, and the acceptability assessed using the at-
trition rate (%) [49]. The outcome data was assessed
based on the amount of missing data (%) found in each
case report form.
The patch and non-patch groups were compared descrip-
tively at baseline. At 6month follow-up, differences be-
tween the medians in each group and associated 95%
confidence intervals were assessed using quantile regres-
sion, adjusting for baseline scores. The groups were also
compared for the proportions in each group that had im-
provement greater than the previously-reported minimum
clinically important difference (MCID) in each shoulder-
specific outcome measure [50]. This was expressed as per-
centages and odds ratios with 95% CI and adjusted for the
baseline score for each outcome. MCID for OSS was set at
5 units, SPADI at 15.4 [51] and Constant score at 10.4 [52].
No hypothesis testing was undertaken as the study did not
aim to draw inferences from the data.
Exploratory sub-group analysis
To further understand outcomes, sub-group analyses
were performed. The patch group was further sub-
divided into a ‘Patch-better Group’, where the surgeon
subjectively rated the patch repair to involve relatively
good quality tendon as noted at surgery (i.e. little
delamination, thick tendon), and a ‘Patch-poor Group’
with massive tears retracted to the level of the glenoid
with poor quality tendons (i.e. frayed, delaminated
thinned tendon). The control group was also sub-
divided into those who underwent an arthroscopic repair
(Non-patch arthroscopy Group) and those who under-
went simple arthroscopic surgery, including debridement
(Non-patch excluding arthroscopy Group). Comparisons
were made between i) the patch poor group and the
patch better group and ii) the non-patch arthroscopy
and the non-patch excluding arthroscopy using quantile




A total of 81 patients were invited to participate, of whom
75 agreed to take part in the study (conversion to con-
sent = 92.6%) and 72 met the eligibility criteria (rate of eli-
gibility = 96.3%). Of the 72 recruited into the study four
patients were withdrawn at baseline: 3 did not have a
RoCT at baseline (2 on MRI and 1 on arthroscopy), and
one patient asked to be withdrawn having undergone no
surgical procedure. Therefore a total of 68 participants
were allocated to an intervention arm: 29 to the patch
group and 39 to the non-patch (control) group (Fig. 3).
Baseline characteristics were balanced across treat-
ment arms (Table 1). Participants were on average (SD)
65.3 years old (9.18), 61% women, BMI of 28.8 (5.69)
with symptom duration of a median 12 months.
Clinical outcome measures
There was a 100% completion rate for all questionnaires
at baseline with respect to calculation of outcome scores,
however 6 individuals (9%) (3 in each treatment arm)
had missing data for the clinician-measured “range of
motion” and “power” components of the Constant score
(Table 2). At 6 months, completion rates to enable cal-
culation of total scores across all questionnaires were
high (90–97%), with slightly more missing data in the
nonpatch group compared to the patch group.
Adherence & acceptability
The initial recruitment target of 60 participants (30 per
arm) was achieved. Clinical data was collected using stan-
dardised outcome measures as set out in the protocol.
The original protocol defined follow-up at 6 weeks and 6
months, however patients undergoing any form of surgery
were struggling to perform the movement and strength el-
ements of some of the outcome measures at 6 weeks. The
6 week follow-up visit was therefore stopped.
Overall attrition from the study at 6 months was mod-
erate (16%), suggesting that the protocol was acceptable.
A difference was observed in attrition between the patch
Fig. 2 Areas contoured on OSIRIX. Green – Supraspinatus (SSP), Blue
– Supraspinatus fossa (SSP_T), Pink – supraspinatus remnant
(SSP_RM), Yellow – infraspinatus (ISP), Red – tangent line with
normal TS
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and non-patch group (1 participant in the patch vs 10 in
the non-patch group); half of the non-patch patients lost
to follow-up were in the physiotherapy group. The mean
follow up time from ‘date of procedure’ to 6month follow-up
was 227 days from an initial target of 180 days (6months).
Clinical outcomes
Improvement was seen at follow-up for all clinical out-
comes in both patch and control groups, except for the
EQ-VAS which was slightly reduced in the control group
(Table 3). Overall, improvements in the patch group
were of a greater magnitude than for the non-patch con-
trol group. The median score was higher in the patch
group compared to controls for the OSS (baseline-ad-
justed difference 9.76, 95% CI 2.25, 17.29, p = 0.01) and
lower for SPADI (difference 22.97, 95% CI 3.0, 42.92,
p = 0.03) but no substantive differences were seen for
the total Constant score (p = 0.59). Compared to the
non-patch group, the patch group had a greater propor-
tion of participants demonstrating improvement (change
greater than MCID) in two of the shoulder-specific pa-
tient reported outcomes, although not statistically sig-
nificant: 78% vs 62% for OSS (Odds ratio 2.94, 95% CI
0.78, 11.02,p = 0.11); 63% vs 50% for SPADI (Odds ratio
2.66,95% CI 0.72,9.78, p = 0.15) but had a lower
proportion of participants demonstrating improvement
for the Constant score (50% vs 62% [Odds ratio 0.57,
95% CI 0.18,1.90,p = 0.35)]. Quality of life scores (EQ-
5D Index and EQ-VAS) were slightly improved in the
patch group compared to the non-patch group.
Exploratory sub-group analysis
Results of the sub-analyses showed no substantive differ-
ences, all p > 0.05 (Table 4). All comparator groups showed
improvement at 6-month follow up with slight variation in
the magnitude between them. Compared to the patch-poor
group, the patch-better group had better improvement in
the Constant score (9.6 score difference between the groups)
and less improvement in SPADI (2.4 score difference) having
adjusted for their baseline scores; and no difference between
the groups for OSS. The non-patch (excluding arthroscopy)
group improved by a greater magnitude compared to the
non-patch arthroscopy group in all 3 outcome scores al-
though this was also not substantive.
MRI outcomes
Of the 68 patients eligible for the study, 58 underwent
MRI at baseline. Of the patients who did not have a
baseline MRI, eight had metallic implants contraindi-
cated to MRI, while one suffered claustrophobia.
Fig. 3 Participant flow diagram
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Table 2 Summary of findings against 9 methodological issues for feasibility research
Methodological issues Findings Evidence
1. Did the feasibility /pilot study
allow a sample size calculation for
the main trial?
Achieved, estimates obtained suitable for sample size
determination for a trial. Measures of dispersion
obtained (median and IQR). Effect size measures
(differences in medians between groups obtained)
and absolute differences between patch and control
groups.
Tables 1 and 2 provide the estimates obtained for
different outcomes.
2. What factors influenced
eligibility and what proportion of
those approached were eligible?
No evidence of cuff tears and participant refusal. Following the initial ultrasound and clinical examination
which indicated presence of a massive cuff tear, 3
patients were found to be ineligible after MRI (2
patients) or arthroscopy (1 participant) found no
evidence of a cuff tear. 1 participant asked to withdraw
from the study prior to baseline.
3. Was recruitment successful? Recruitment was successful. High recruitment due to
cross-referrals from upper limb surgeons in the same
unit.
Of the potential 75 participants identified, 72 were
recruited.
4. Did eligible participants
consent?
High conversion to consent 100% conversion rate (Fig.1) all 72 that consented were
allocated to a study arm
5. Was the intervention
acceptable to the participants?
Not directly assessed but the high numbers recruited
suggest little difficulty.
68 (94%) out of a possible 72 entered the study after
consenting
6. Were outcome assessments
completed?
Completion rate was 100% for all questionnaires at
baseline Questionnaire completion rates varied at 6
months.
Oxford score 6 month questionnaire (patch 27/28 and
controls 26/29) completed
SPADI 6 month questionnaire (patch 28/28 and controls
28/29) completed
Constant score 6 month questionnaire (patch 28/29 and
controls 26/29) completed.
7. Were outcomes measured
those that were the most
appropriate outcomes?
All questionnaires assessed main areas of interest
(shoulder pain and function) and also patient quality
of life
All participants completed all items at baseline
8. Was retention to the study
good?
Once recruited retention was very good for the
patch group but appeared lower in the control
group
1 patch patient with no 6 month data and 10 control
patients with no 6month outcome data
9. Did all the components of the
protocol work together?
The study was a success as most components
worked well
Recruitment went smoothly, 68 recruited in total from
an initial estimate of 60 required
Methodological issues based on Shanyinde et al. (28) and Bugge et al. (29)
Table 3 Summary of outcome measurers by treatment group over 6 month follow up





valueBaseline 6 months Baseline 6 months
Oxford score (/48) 28 (21–34) 42 (35–47) 25 (20–30) 34 (26–44) 9.7 (2.3,17.3) 0.01
SPADI 46.9 (30.8–71.5) 16.9 (6.9–28.5) 54.6 (42.3–66.9) 39.6 (8.9–53.5) 23.0 (3.0,42.9) 0.03
EQ-5D Index 0.70 (0.53–0.82) 0.89 (0.82–0.94) 0.72 (0.55–0.80) 0.78 (0.51–0.94) 0.11 (− 0.04,0.27) 0.15
EQ-5D VAS 75 (54–80) 80 (70–90) 75 (65–90) 70 (60–80) 10 (−0.7,20.7) 0.07
Constant score (CS) Total (/100) 44 (27–54.5) 57.8 (45.8–66.5) 42.0 (33.5–51.9) 55.5 (43.5–64) 3.0 (−8.1,14.2) 0.59
Pain CS score (/15) 8 (6.5–8.5) 2.5 (1.0–4.5) 8.5 (7–9) 2.5 (1.0–4.5) 0.00 (−2.0,2.0) 0.99
ADL CS score (/20) 8 (5–10) 16 (13–19) 8 (6–10) 10 (8–18) 6.0 (1.7,10.3) 0.01
ROM CS score (/40) 24 (14–32) 33 (27–39) 25 (18–30) 35 (24–40) 4.0 (−11.4,3.4) 0.28
Power CS score (/25) 4 (2–4) 6.0 (2–10) 4 (2–7) 6.0 (4–10) 1.3 (−5.0,2.4) 0.50
*Results from quantile regression adjusting for baseline score
*Values are median (IQR)
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Another patient attended the scan, but could not toler-
ate it so it was halted prematurely without sufficient im-
ages for analysis. At 6 month follow-up 54/58 underwent
MRI, meaning 4 additional patients declining or not at-
tending, alongside the still contraindicated 10 patients
from baseline, totalling 14 who did not have the 6 month
MRI. On analysis of the MRI scans, for 4 patients, the
fat and water images could not be reconstructed from
the “in” and “out of” phase images. One patient was im-
aged in the wrong plane: a technical error in MRI proto-
col. One patient subsequently withdrew from the study,
so their data was not analysed. This resulted in 48 par-
ticipants with paired MRI scores available: 22 in the
Patch group, and 26 in the non-patch group. Complete
paired Goutallier data was available for 41 participants.
In the full sample, there was only a slight increase in the fat
fraction for supraspinatus (SSP; 53 to 55%) and the infraspina-
tus (ISP; 26 to 29%) while the supraspinatus remnant (SSP_
RM) showed no change (Table 5). These differences were
similar and in the same direction when the participants were
analysed separately by treatment status (patch vs nonpatch).
A change in Goutallier classification was defined as a
difference of at least 1 grade. For the SSP, 11 partici-
pants worsened over time (5 in the controls and 6 in the
patch), while 30 remained the same and 1 improved. Re-
sults were similar for ISP and teres minor.
Discussion
The primary aim of this study was to determine the feasibil-
ity of conducting a randomised controlled trial using patch-
assisted surgery. A definitive randomised control trial ap-
pears achievable in terms of recruitment, eligibility, accept-
ability and outcome measures. The secondary aim was to
compare the clinical outcomes of patients with massive
RoCTs who were managed with patch-assisted surgery
against patients managed with traditional treatment options
(non-surgical physiotherapy-based rehabilitation, arthro-
scopic repair, and arthroscopic debridement). Improve-
ments in shoulder symptoms were found in both patch and
control groups at 6months, but a greater magnitude of im-
provement was observed in patients receiving patch repair.
To our knowledge this is the first study to compare
synthetic patch repair with a number of common treat-
ment modalities for large and massive rotator cuff tears,
including conservative management. It is also novel to
include MRI analysis of the rotator cuff before and after
these treatment modalities. Previous studies investigating
patch augmentation of large or massive rotator cuff re-
pairs have mainly been case series [21, 31, 32] . Few
studies comparing synthetic patch to other treatment
methods for symptomatic rotator cuff tear have been re-
ported. These generally involve similar patient num-
bers with massive RoCTs to the current study
(ranging from 21 to 60 patients with patch repair),
and include a comparison of the synthetic patch with
no patch [53]; a comparison with biological collagen
patch as well as standard repair group [54]; a com-
parison of patch plus bone marrow and arthroscopic
cuff repair [55]; and patch Vs partial repair [56]. The
synthetic patch demonstrated a lower retear rate, and
Table 4 Sub-group comparisons between patch and non-patch groups over 6 month follow up
Group Oxford score SPADI Constant score
Patch poor
Baseline 24 (21–36) 51.5 (31.5–73.1) 34 (27–58)
6 months 42 (35–48) 16.2 (6.2–17.7) 53 (40.5–65.5)
Patch better
Baseline 29 (21–34) 38.8 (29.9–71.5) 45.5 (24–54.5)
6 months 42 (40–46) 20 (11.5,28.5) 58.5 (55.5–66.5)
*Difference in medians (95% CI) 0.0 (−8.2,8.2) 2.4 (−21.6,26.3) 9.6 (−5.9,25.2)
P-value 0.99 0.84 0.21
Non-patch arthroscopy
Baseline 23.5 (19.5–29) 61.9 (40.4–67.7) 44.3 (37.5–50.2)
6 months 29 (29–31) 42.3 (10.8,49.4) 49.5 (43.5–64)
Non-patch (excluding arthroscopy)
Baseline 26 (21–30) 51.5 (42.3–61.5) 41.5 (31–53.1)
6 months 35.5 (25.5–45.5) 30 (6.9–53.5) 56.5 (41.5–63.5)
*Difference in medians (95% CI) −5.6 (−9.5,20.7) 2.36 (−34.9,39.6) 2.83 (−14.4,20.1)
P-value 0.45 0.90 0.74
* Results at 6 months from quantile regression adjusting for baseline score
Values are median (IQR)
Cowling et al. BMC Musculoskeletal Disorders          (2020) 21:213 Page 8 of 12
improvement in various functional outcome measures
and strength.
Feasibility outcomes
This feasibility study was designed as a pragmatic study,
and thus randomisation and blinding was not assessed.
A future larger scale study would likely compare patch-
assisted surgery with non-patch assisted surgery, remov-
ing the non-surgical component within this feasibility
study. As such, we would envisage the use of a standar-
dised intra-operative decision system for surgeons,
which would determine whether a participant was eli-
gible for patch-assisted surgery and participants would
be randomised at this point into one of two surgical
treatment arms. Although the surgeon and potentially
the patient (as a result of patch surgery requiring a lar-
ger opening, and therefore a larger scar, than non-patch
arthroscopic surgery) would be aware of the treatment
allocation, an independent assessor could conduct subse-
quent follow-up visits to reduce potential bias.
The moderate attrition rate at 6 months (11 lost to
follow-up) suggests that the protocol was acceptable for
participants; however, we did make the decision to re-
move the 6 week follow-up from the protocol early in
the study due to the difficulty of patients in completing
functional tests so early after any form of surgery. Miss-
ing data was minimal possibly due to the use of a num-
ber of routinely used shoulder questionnaires that were
easy to complete. There was a noticeably lower comple-
tion rate/retention in the non-patch group, with half of
these having received non-surgical management. It is
possible that having made the decision not to proceed
with surgery that these patients became disengaged from
involvement in a ‘surgical’ study and there may also have
been disengagement from the surgical team since these
patients were no longer under their clinical care.
Various scoring systems are quoted in literature for
post-operative assessment of rotator cuff surgery. In this
current study we selected the OSS and Constant score,
since they were the most well validated and frequently
used to determine outcomes of RoCTs [9, 57]. In
Table 5 MRI findings
Whole group (N=68) Patch group (N=29) Non-patch (N=39)
Fat fraction volume (%)
Paired scan data available 48 22 26
Supraspinatus fat fraction (%)
Baseline 53.7 55.0 51.7
6 months 55.0 56.0 54.2
Supraspinatus remnant (%)
Baseline 23.5 24.1 22.9
6 months 24.4 25.8 23.1
Infraspinatus fat fraction (%)
Baseline 25.9 25.4 26.3
6 months 29.1 28.9 29.2
Goutallier classification, N (%)
Paired scan data available 41 18 23
Supraspinatus
Improved 1 (2.4) 1 (5.6) 0 (0)
Worsened 11 (26.8) 6(27.8) 5 (21.7)
Remained the same 29 (70.7) 11 (61.1) 18 (78.3)
Infraspinatus
Improved 2 (4.9) 1 (5.6) 1 (4.3)
Worsened 10 (24.4) 5 (27.8) 5 (21.7)
Remained the same 29 (70.7) 12 (66.7) 17 (74.0)
Teres minor
Improved 3 (7.3) 2 (11.2) 1 (4.3)
Worsened 11 (26.8) 5 (27.8) 6 (26.1)
Remained the same 27 (65.9) 11 (61.1) 16 (69.6)
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addition, we included the SPADI which has been shown
to have reasonable validity and, although devised primar-
ily as a rheumatological outcome score [37, 58], has been
used to assess outcomes of RoCTs in the past [59]. We
found that the Constant score had the most missing data
fields of the three scores, which may reflect the multi-
domain nature of the tool with functional tests which
are difficult for some RoCT patients to complete and a
mixture of patient-reported and clinician-reported out-
comes. A recent systematic review of the psychometric prop-
erties of patient-reported outcomes in patients with rotator
cuff disease found good evidence in support of the measure-
ment properties of SPADI, limited overall evidence for OSS
and mixed evidence for the Constant score, with positive evi-
dence for responsiveness and reliability but negative evidence
for hypothesis testing [60]. A recent international consensus
process involving patients, clinicians and researchers, has de-
fined the core outcome domains for shoulder disorder trials as
‘pain’, ‘physical functioning’, ‘global assessment of treatment
success’ and ‘health-related quality of life’ [61]. Work to define
a core outcome set based on these domains for clinical trials
of people with shoulder pain is ongoing. A future study would
therefore incorporate recommendations from this work to en-
sure alignment with international standards.
The level of MRI acceptability and attendance was
high, despite ten patients with contraindications to such
scans. In addition, the data available from the scans was
of reasonable reliability and accuracy, with only 7 of the
48 paired scans having missing data for analysis of fat
fraction and/or Goutallier Classification, which was due
to technical errors with the protocols set for those pa-
tients’ scans.
Clinical outcomes
This study provides preliminary evidence that any stand-
ard shoulder intervention may provide improvement in
outcome scores, but that patch repair provides greater
improvement in all outcomes at 6 months. The differ-
ences between the patch group and controls were sub-
stantial (greater than MCID) for the Oxford Shoulder
Score. On further subgroup analysis, no substantive dif-
ferences were found between patch patients with good
quality and poor quality tendons, although this finding
may have been hampered by small numbers.
MRI outcomes at 6 months demonstrated little differ-
ence between the patch group and control group, with
both groups demonstrating either similar or slightly
worse (i.e. higher) fat fraction within the rotator cuff. It
may be that 6 months is too early in the rehabilitation
phase following any treatment method to note anatom-
ical changes. To confirm our findings of clinically mean-
ingful improvement using a patch, a definitive trial is
needed.
Limitations
Due to the pragmatic, unblinded nature of the study, a
patient’s treatment wishes were taken into consideration,
which is common practice with surgical interventions. In
this setting this was a feasible and ethical way to conduct
the study but may potentially lead to bias.
This pragmatic nature allows assessment of a number of
treatment measures for massive RoCTs, but this can lead to
a heterogenous comparison group: the non-patch group of
39 patients included those undergoing arthroscopic rotator
cuff repair, arthroscopic debridement of an irreparable tear,
and non-operative physiotherapy management. However, in
terms of participant demographic and baseline characteristics
there were no substantive differences between groups.
The inclusion criteria for the study allowed patients to
be eligible if they had ultrasound or magnetic resonance
imaging (MRI) findings confirming massive rotator cuff
full thickness tears (RoCT) (> 5 cm in size), with un-
acceptable pain and disability following conservative
treatment or previous surgery that had failed and would
be considered for patch surgery under routine clinical
practice. This does mean there is a heterogeneous sam-
ple for both groups, (patch and non-patch) with some
patients having primary massive tears, and others retears
of previously repaired tendons. In this feasibility study,
this was noted but did not form part of the outcome
analysis. This factor could influence outcome measures,
and in any subsequent trial following this feasibility
study, this should be analysed.
The subgroup analysis into tendon quality and de-
gree of retraction is subjective, and due to lower num-
bers compared in each group there was reduced power
in those analyses. However, these analyses highlight
important factors that could be could be useful for
eligibility and stratification purposes in subsequent
trials.
Of the baseline number of 68 participants, only 58
underwent MRI assessment prior to any intervention:, 8
participants did not have an MRI at baseline due to metal-
lic implants, 1 due to claustrophobia and another became
claustrophobic during the first scan. Therefore, although
patients had legitimate reasons for failure to complete
MRI assessment, this led to a reduction in the number of
scans possible to assess. For this reason, we amended the
protocol to allow additional recruitment to the study to
compensate for those ineligible for the MRI. At 6months,
a further 4 declined or failed to attend. The drop-out rate
for those eligible for MRI assessment was acceptable, sug-
gesting that the MRI was an acceptable component of the
protocol, although over a longer follow-up it is possible
that this number would decrease further.
The two point Dixon imaging technique employed did
not correct for T2* effects, eddy currents, noise related
bias or the spectral complexity of fat.
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Conclusion
Promising short-term results can be achieved using
patch augmentation for massive RoCTs. This study sug-
gests that a patch may be beneficial, and given the posi-
tive outcomes from this study, a larger trial to
investigate patch surgery is feasible.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12891-020-03227-z.
Additional file 1 Table S1. Description of surgical interventions
Abbreviations
BMI: Body mass index; CI: Confidence interval; EQ-5D-5 L: EuroQol five
dimensions questionnaire; ISP: Infraspinatus; MCID: Minimum clinically
important difference; MRI: Magnetic resonance imaging; OSS: Oxford
Shoulder Score; PET: Polyethylene terephthalate; RoCT: Rotator cuff tear;
SPADI: Shoulder Pain and Disability Index; SSP: Supraspinatus;
SSP_RM: Supraspinatus remnant; TS: Tangent sign; UCLA: University of
California at Los Angles; VAS: Visual analogue score; VIBE: Volumetric
interpolated breath-hold examination
Acknowledgements
We are grateful to Mo Ismail, Anand Karmegan, Krishna Kumar, Ravi
Putteswamiah and Simon Fogarty for support with participant recruitment
and data collection.
Authors’ contributions
RH – study concept and design, acquisition of data, drafting manuscript, final
approval; BD – data analysis and interpretation of data, drafting manuscript,
final approval; PC – acquisition of data, data analysis and interpretation of data,
drafting manuscript, final approval; AG, JDB, MS, DS - data analysis and
interpretation of data, drafting manuscript, final approval; PGC - study concept
and design, drafting manuscript, final approval; SRK - study concept and design,
acquisition of data, data analysis and interpretation of data, drafting manuscript,
final approval. The author(s) read and approved the final manuscript.
Funding
This study was funded by a Leeds Teaching Hospitals Charitable Foundation
Pilot Project Award (Ref R&D/PP/1305). PG, SRK and BD are supported by the
Arthritis Research UK Experimental Osteoarthritis Treatment Centre (Ref
20083) and the UK NIHR Leeds Biomedical Research Centre. JDB is funded by
a National Institute for Health Research and Health Education England,
Clinical Lectureship. This paper presents independent research funded by
the National Institute for Health Research (NIHR) and Health Education
England. The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the UK Department of Health.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
All participants provided written informed consent prior to enrolment into





RH - consults for Xiros, Leeds UK, and received fees for each patch used by
another surgeon. BD, PC, AJG, JDB, MS, DS, PGC, SRK declare that they have
no competing interests.
Author details
1Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Chapeltown
Road, Leeds LS7 4SA, UK. 2NIHR Leeds Biomedical Research Centre, Leeds,
UK. 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University
of Leeds, Leeds, UK. 4Leeds Medical School, University of Leeds, Leeds, UK.
Received: 9 September 2019 Accepted: 20 March 2020
References
1. Linsell L, Dawson J, Zondervan K, Rose P, Randall T, Fitzpatrick R, et al.
Prevalence and incidence of adults consulting for shoulder conditions in UK
primary care; patterns of diagnosis and referral. Rheumatology (Oxford).
2006;45:215–21.
2. Mitchell C, Adebajo A, Hay E, Carr A. Shoulder pain: diagnosis and
management in primary care. Bmj. 2005;331:1124–8.
3. Sakurai G, Ozaki J, Tomita Y, Kondo T, Tamai S. Incomplete tears of the
subscapularis tendon associated with tears of the supraspinatus tendon:
cadaveric and clinical studies. J Shoulder Elb Surg. 1998;7:510–5.
4. Aoki M, Okamura K, Fukushima S, Takahashi T, Ogino T. Transfer of latissimus
dorsi for irreparable rotator-cuff tears. J Bone Joint Surg Br. 1996;78:761–6.
5. Moore DR, Cain EL, Schwartz ML, Clancy WG Jr. Allograft reconstruction for
massive, irreparable rotator cuff tears. Am J Sports Med. 2006;34:392–6.
6. DeOrio JK, Cofield RH. Results of a second attempt at surgical repair of a
failed initial rotator-cuff repair. J Bone Joint Surg Am. 1984;66:563–7.
7. Rees JL. The pathogenesis and surgical treatment of tears of the rotator
cuff. J Bone Joint Surg Br. 2008;90:827–32.
8. Fuchs B, Gilbart MK, Hodler J, Gerber C. Clinical and structural results of
open repair of an isolated one-tendon tear of the rotator cuff. J Bone Joint
Surg Am. 2006;88:309–16.
9. Carr A, Cooper C, Campbell MK, Rees J, Moser J, Beard DJ, et al.
Effectiveness of open and arthroscopic rotator cuff repair (UKUFF). Bone
Joint J. 2017;99-B:107.
10. Gurnani N, van Deurzen DFP, van den Bekerom MPJ. Shoulder-specific
outcomes 1 year after nontraumatic full-thickness rotator cuff repair: a
systematic literature review and meta-analysis. Shoulder Elbow. 2017;9:247–57.
11. Bjorkenheim JM, Paavolainen P, Ahovuo J, Slatis P. Surgical repair of the
rotator cuff and surrounding tissues. Factors influencing the results. Clin
Orthop Relat Res. 1988:148–53.
12. Gazielly DF, Gleyze P, Montagnon C. Functional and anatomical results after
rotator cuff repair. Clin Orthop Relat Res. 1994:43–53.
13. Harryman DT 2nd, Mack LA, Wang KY, Jackins SE, Richardson ML, Matsen FA
3rd. Repairs of the rotator cuff. Correlation of functional results with
integrity of the cuff. J Bone Joint Surg Am. 1991;73:982–9.
14. Thomazeau H, Boukobza E, Morcet N, Chaperon J, Langlais F. Prediction of
rotator cuff repair results by magnetic resonance imaging. Clin Orthop Relat
Res. 1997:275–83.
15. Duralde XA, Bair B. Massive rotator cuff tears: the result of partial rotator cuff
repair. J Shoulder Elb Surg. 2005;14:121–7.
16. Franceschi F, Papalia R, Vasta S, Leonardi F, Maffulli N, Denaro V. Surgical
management of irreparable rotator cuff tears. Knee Surg Sports Traumatol
Arthrosc. 2015;23:494–501.
17. Burkhart SS. Arthroscopic treatment of massive rotator cuff tears. Clin
Orthop Relat Res. 2001:107–18.
18. Liem D, Lengers N, Dedy N, Poetzl W, Steinbeck J, Marquardt B.
Arthroscopic debridement of massive irreparable rotator cuff tears.
Arthroscopy. 2008;24:743–8.
19. Lo IK, Burkhart SS. Arthroscopic repair of massive, contracted, immobile
rotator cuff tears using single and double interval slides: technique and
preliminary results. Arthroscopy. 2004;20:22–33.
20. Berth A, Neumann W, Awiszus F, Pap G. Massive rotator cuff tears:
functional outcome after debridement or arthroscopic partial repair. J
Orthop Traumatology. 2010;11:13–20.
21. Castagna A, Garofalo R, Cesari E. No prosthetic management of massive and
irreparable rotator cuff tears. Shoulder Elbow. 2014;6:147–55.
22. Delaney RA, Lin A, Warner JJ. Nonarthroplasty options for the management of
massive and irreparable rotator cuff tears. Clin Sports Med. 2012;31:727–48.
23. Irlenbusch U, Bracht M, Gansen HK, Lorenz U, Thiel J. Latissimus dorsi
transfer for irreparable rotator cuff tears: a longitudinal study. J Shoulder Elb
Surg. 2008;17:527–34.
Cowling et al. BMC Musculoskeletal Disorders          (2020) 21:213 Page 11 of 12
24. Merolla G, Chillemi C, Franceschini V, Cerciello S, Ippolito G, Paladini P, et al.
Tendon transfer for irreparable rotator cuff tears: indications and surgical
rationale. Muscles Ligaments Tendons J. 2014;4:425–32.
25. Galatz LM, Ball CM, Teefey SA, Middleton WD, Yamaguchi K. The outcome
and repair integrity of completely arthroscopically repaired large and
massive rotator cuff tears. J Bone Joint Surg Am. 2004;86-a:219–24.
26. Gerber C, Fuchs B, Hodler J. The results of repair of massive tears of the
rotator cuff. J Bone Joint Surg Am. 2000;82:505–15.
27. Senekovic V, Poberaj B, Kovacic L, Mikek M, Adar E, Markovitz E, et al. The
biodegradable spacer as a novel treatment modality for massive rotator cuff
tears: a prospective study with 5-year follow-up. Arch Orthop Trauma Surg.
2017;137:95–103.
28. Badhe SP, Lawrence TM, Smith FD, Lunn PG. An assessment of porcine
dermal xenograft as an augmentation graft in the treatment of extensive
rotator cuff tears. J Shoulder Elbow Surg. 2008;17:35s–9s.
29. Nada AN, Debnath UK, Robinson DA, Jordan C. Treatment of massive
rotator-cuff tears with a polyester ligament (Dacron) augmentation: clinical
outcome. J Bone Joint Surg Br. 2010;92:1397–402.
30. Burkhead WZ Jr, Schiffern SC, Krishnan SG. Use of graft jacket as an
augmentation for massive rotator cuff tears. Semin Arthroplast. 2007;18:11–8.
31. Kim SJ, Lee IS, Kim SH, Lee WY, Chun YM. Arthroscopic partial repair of
irreparable large to massive rotator cuff tears. Arthroscopy. 2012;28:761–8.
32. Arrigoni P, Fossati C, Zottarelli L, Ragone V, Randelli P. Functional repair in
massive immobile rotator cuff tears leads to satisfactory quality of living:
results at 3-year follow-up. Musculoskelet Surg. 2013;97(Suppl 1):73–7.
33. Rangan A, Upadhaya S, Regan S, Toye F, Rees JL. Research priorities for
shoulder surgery: results of the. James Lind Alliance patient and clinician
priority setting partnership. BMJ Open. 2015;2016:6.
34. Legnani C, Ventura A, Terzaghi C, Borgo E, Albisetti W. Anterior cruciate
ligament reconstruction with synthetic grafts. A review of literature. Int
Orthop. 2010;34:465–71.
35. Sinagra ZP, Kop A, Pabbruwe M, Parry J, Clark G. Foreign body reaction
associated with artificial LARS ligaments: a retrieval study. Orthop J Sports
Med. 2018;6:2325967118811604.
36. Dawson J, Rogers K, Fitzpatrick R, Carr A. The Oxford shoulder score
revisited. Arch Orthop Trauma Surg. 2009;129:119–23.
37. Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y. Development of a
shoulder pain and disability index. Arthritis Care Res. 1991;4:143–9.
38. Constant CR, Murley AH. A clinical method of functional assessment of the
shoulder. Clin Orthop Relat Res. 1987:160–4.
39. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al.
Development and preliminary testing of the new five-level version of EQ-5D
(EQ-5D-5L). Qual Life Res. 2011;20:1727–36.
40. Zanetti M, Gerber C, Hodler J. Quantitative assessment of the muscles of the
rotator cuff with magnetic resonance imaging. Investig Radiol. 1998;33:163–70.
41. Goutallier D, Postel JM, Bernageau J, Lavau L, Voisin MC. Fatty muscle
degeneration in cuff ruptures. Pre- and postoperative evaluation by CT scan.
Clin Orthop Relat Res. 1994:78–83.
42. Billingham SAM, Whitehead AL, Julious SA. An audit of sample sizes for pilot
and feasibility trials being undertaken in the United Kingdom registered in
the United Kingdom clinical research network database. BMC Med Res
Methodol. 2013;13:104.
43. Hertzog MA. Considerations in determining sample size for pilot studies. Res
Nurs Health. 2008;31:180–91.
44. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample
size for a pilot randomised trial to minimise the overall trial sample size for
the external pilot and main trial for a continuous outcome variable. Stat
Methods Med Res. 2016;25:1057–73.
45. Moore C, Nietert S. Recommendations for planning pilot studies in clinical
and translational research. Clin Translational Sci. 2011;4:332–7.
46. Shanyinde M, Pickering RM, Weatherall M. Questions asked and answered in
pilot and feasibility randomized controlled trials. BMC Med Res Methodol.
2011;11:117.
47. Bugge C, Williams B, Hagen S, Logan J, Glazener C, Pringle S, et al. A
process for decision-making after pilot and feasibility trials (ADePT):
development following a feasibility study of a complex intervention for
pelvic organ prolapse. Trials. 2013;14:353.
48. Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials:
should significance thresholds be reconsidered? BMCMed Res Methodol. 2014;14:41.
49. Dettori JR. Loss to follow-up. Evid Based Spine Care J. 2011;2:7–10.
50. Ekeberg OM, Bautz-Holter E, Keller A, Tveitå EK, Juel NG, Brox JI. A
questionnaire found disease-specific WORC index is not more responsive than
SPADI and OSS in rotator cuff disease. J Clin Epidemiol. 2010;63:575–84.
51. Kukkonen J, Kauko T, Vahlberg T, Joukainen A, Äärimaa V. Investigating
minimal clinically important difference for Constant score in patients
undergoing rotator cuff surgery. J Shoulder Elb Surg. 2013;22:1650–5.
52. Vitali M, Cusumano A, Pedretti A, Naim Rodriguez N, Fraschini G.
Employment of synthetic patch with augmentation of the long head of the
biceps tendon in irreparable lesions of the rotator cuff: our technique
applied to 60 patients. Tech Hand Up Extrem Surg. 2015;19:32–9.
53. Ciampi P, Scotti C, Nonis A, Vitali M, Di Serio C, Peretti GM, et al. The benefit
of synthetic versus biological patch augmentation in the repair of
posterosuperior massive rotator cuff tears: a 3-year follow-up study. Am J
Sports Med. 2014;42:1169–75.
54. Yoon JP, Chung SW, Kim JY, Lee BJ, Kim HS, Kim JE, et al. Outcomes of
combined bone marrow stimulation and patch augmentation for massive
rotator cuff tears. Am J Sports Med. 2016;44:963–71.
55. Mori D, Funakoshi N, Yamashita F. Arthroscopic surgery of irreparable large
or massive rotator cuff tears with low-grade fatty degeneration of the
infraspinatus: patch autograft procedure versus partial repair procedure.
Arthroscopy. 2013;29:1911–21.
56. Piper CC, Hughes AJ, Ma Y, Wang H, Neviaser AS. Operative versus nonoperative
treatment for the management of full-thickness rotator cuff tears: a systematic
review and meta-analysis. J Shoulder Elb Surg. 2018;27:572–6.
57. Varghese M, Lamb J, Rambani R, Venkateswaran B. The use of shoulder
scoring systems and outcome measures in the UK. Ann R Coll Surg Engl.
2014;96:590–2.
58. Roy JS, MacDermid JC, Woodhouse LJ. Measuring shoulder function: a
systematic review of four questionnaires. Arthritis Rheum. 2009;61:623–32.
59. Huang H, Grant JA, Miller BS, Mirza FM, Gagnier JJ. A systematic review of
the psychometric properties of patient-reported outcome instruments for
use in patients with rotator cuff disease. Am J Sports Med. 2015;43:2572–82.
60. Page MJ, Huang H, Verhagen AP, Buchbinder R, Gagnier JJ. Identifying a
core set of outcome domains to measure in clinical trials for shoulder
disorders: a modified Delphi study. RMD Open. 2016;2:e000380.
61. Gagnier JJ, Page MJ, Huang H, Verhagen AP, Buchbinder R. Creation of a
core outcome set for clinical trials of people with shoulder pain: a study
protocol. Trials. 2017;18:336.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Cowling et al. BMC Musculoskeletal Disorders          (2020) 21:213 Page 12 of 12
